<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457844</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-13-II</org_study_id>
    <nct_id>NCT03457844</nct_id>
  </id_info>
  <brief_title>A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3</brief_title>
  <official_title>A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic&#xD;
      Neuroendocrine Tumor G3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>From randomization，each 42 days up to progressive disease(PD) or death(up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>From randomization until death (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastroenteropancreatic Neuroendocrine Tumor G3</condition>
  <arm_group>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients should participate in the study voluntarily and sign informed consent;&#xD;
&#xD;
          -  18-75 years old;&#xD;
&#xD;
          -  Histopathological proven diagnosis of high grade (G3) advanced Gastroenteropancreatic&#xD;
             Neuroendocrine Tumor(Unresectable locally advanced or distant Metastatic). the&#xD;
             classification is based on the Ki-67 proliferative index &gt;20%(WHO 2010),and Provision&#xD;
             of qualified pathological tissue for central review;&#xD;
&#xD;
          -  Progression during or after treatment with first-line systematic chemotherapy;&#xD;
&#xD;
          -  At least one measurable nidus (by RECIST1.1);&#xD;
&#xD;
          -  Main organs function is normal;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) performance status(PS):0-1,Life expectancy of&#xD;
             more than 12 weeks;&#xD;
&#xD;
          -  Women of childbearing potential should agree to use and utilize an adequate method of&#xD;
             contraception (such as intrauterine device，contraceptive and condom) throughout&#xD;
             treatment and for at least 6 months after study is stopped；the result of serum or&#xD;
             urine pregnancy test should be negative within 7 days prior to study enrollment，and&#xD;
             the patients required to be non-lactating；Man participants should agree to use and&#xD;
             utilize an adequate method of contraception throughout treatment and for at least 6&#xD;
             months after study is stopped;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with low or intermediate (G1,G2) neuroendocrine tumors, Manec,&#xD;
             adenocarcinoma;&#xD;
&#xD;
          -  Functional neuroendocrine tumors(NETs) which need to be treated with long acting&#xD;
             somatostatin analogue(SSAs) to control disease related syndromes, such as insulinoma,&#xD;
             gastrinoma, glucagonoma, somatostatinoma, accompanied by carcinoid syndrome,&#xD;
             Zollinger-Ellison syndrome or other active symptoms;&#xD;
&#xD;
          -  Other malignancies diagnosed within the previous 5 years, except basal cell carcinoma&#xD;
             or cervical carcinoma in situ after radical resection；&#xD;
&#xD;
          -  Have received anti-vascular endothelial growth factor（VEGF）/VEGFR targeted drugs and&#xD;
             progressed upon these drugs；&#xD;
&#xD;
          -  Patients with factors that could affect oral medication (such as dysphagia，chronic&#xD;
             diarrhea, intestinal obstruction etc.)&#xD;
&#xD;
          -  Patients with any severe and/or unable to control diseases，including：&#xD;
&#xD;
               1. Blood pressure unable to be controlled ideally(systolic pressure≥150&#xD;
                  mmHg，diastolic pressure≥100 mmHg);&#xD;
&#xD;
               2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or&#xD;
                  malignant arrhythmias(including QT≥480ms) and patients with Grade 1 or higher&#xD;
                  congestive heart failure (NYHA Classification);&#xD;
&#xD;
               3. Patients with active or unable to control serious infections;&#xD;
&#xD;
               4. Patients with cirrhosis, decompensated liver disease, or active hepatitis;&#xD;
&#xD;
               5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)&gt;10mmol/L)&#xD;
&#xD;
               6. Urine protein ≥ ++，and 24-hour urinary protein excretion&gt;1.0g confirmed;&#xD;
&#xD;
          -  Patients had surgery (except biopsy) within 28 days or the surgical incision has not&#xD;
             fully healed before the first study drug implementation;&#xD;
&#xD;
          -  Patients with brain metastasis or spinal cord compression which had not surgical and /&#xD;
             or radiation therapy,or which had previous treatment but there is no clinical imaging&#xD;
             evidence proving the condition is stable;&#xD;
&#xD;
          -  Anti-tumor therapy was performed within 4 weeks prior to initiation of the study&#xD;
             treatment, including but not limited to chemotherapy, radical radiotherapy,&#xD;
             bio-targeted therapy, immunotherapy, anti-tumor treatment of traditional Chinese&#xD;
             medicine, hepatic artery embolization, hepatic metastatic cryoablation or&#xD;
             radiofrequency ablation surgery.Palliative radiotherapy for a bone metastasis lesion&#xD;
             within 2 weeks prior to the initiation of the investigational treatment;&#xD;
&#xD;
          -  The toxic reaction of previous anticancer treatment has not been restored to grade 0&#xD;
             or 1 (except hair loss);&#xD;
&#xD;
          -  Patients with arterial or venous thromboembolic events occurred within 6 months, such&#xD;
             as cerebrovascular accident (including transient ischemic attack), deep vein&#xD;
             thrombosis and pulmonary embolism;&#xD;
&#xD;
          -  Imaging showed tumors have involved important blood vessels or by investigators&#xD;
             determine likely during the follow-up study and cause fatal hemorrhage;&#xD;
&#xD;
          -  Patients with drug abuse history and unable to get rid of or Patients with mental&#xD;
             disorders;&#xD;
&#xD;
          -  Patients participated in other anticancer drug clinical trials within 4 weeks;&#xD;
&#xD;
          -  History of immunodeficiency;&#xD;
&#xD;
          -  Pregnancy(Positive detection of pregnancy before drug use)or lactation;&#xD;
&#xD;
          -  Patients with concomitant diseases which could seriously endanger their own safety or&#xD;
             could affect completion of the study according to investigators' judgment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yihebali Chi, doctor</last_name>
    <phone>010-67781331</phone>
    <email>dryihebalichi@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yihebali Chi</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihebali Chi, doctor</last_name>
      <phone>010-67781331</phone>
      <email>dryihebalichi@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

